Back to search
FDAFDA · Food and drugs·Recall number D-0891-2023

Amphotericin B Liposome for Injection, 50mg/vial, Rx only, Distributed by Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512, Manufactured by Sun Pharmaceutical Medicare Limited, Baska Ujeti Road, Ujeti, Halol-389350, Gujarat, India, NDC 62756-0233-01

Published July 5, 2023 · Recall initiated: May 30, 2023

Summary

FDA records drug Class II recall D-0891-2023, published July 5, 2023 and initiated May 30, 2023. Recalling firm: SUN PHARMACEUTICAL INDUSTRIES INC; Status: Terminated; Reported quantity: 12960 vials; Lot: Lot # BAD0089A, Exp 01/2025; BAD0330A, Exp 07/2025. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Subpotent drug

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
SUN PHARMACEUTICAL INDUSTRIES INC
Distributor
USA nationwide
Lot
Lot # BAD0089A, Exp 01/2025; BAD0330A, Exp 07/2025
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Amphotericin B Liposome for Injection, 50mg/vial, Rx only, Distributed by Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512, Manufactured by Sun Pharmaceutical Medicare Limited, Baska Ujeti Road, Ujeti, Halol-389350, Gujarat, India, NDC 62756-0233-01 recalled?

Yes. FDA published recall D-0891-2023 on July 5, 2023. Reported hazard: Subpotent drug

What should I do if I have this product?

Stop using or selling the product and check the official FDA notice (D-0891-2023) for return or repair instructions.